Plan-Les-Ouates/Switzerland– 26th July 2010 - NovImmune, an antibody-focused research and development biotech company, announced today that it successfully entered into an exclusive licensing agreement with Genentech Inc. a  member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for a proprietary anti-IL-17 fully human monoclonal antibody, and access to back-up antibodies. Recently, the IL-17 signaling pathway has received significant academic and corporate interest as its manipulation may potentially provide new treatment opportunities for major medical conditions.

The anti-IL-17 antibody was generated by NovImmune’s research team and is currently in late preclinical development. Under the terms of the agreement NovImmune will receive an upfront payment and is eligible to receive clinical milestones and royalties on sales.  Full financial terms  have not been disclosed.

Jack Barbut, CEO, commented “We believe Genentech is the right partner for NovImmune for this program. Genentech brings an in-depth understanding of IL-17 biology and extensive experience in its ability to potentially identify patient populations that may benefit from such a compound thus maximizing chances of successful development.” 

James Sabry, Vice President of Genentech Partnering, said “Genentech is very pleased to have the opportunity to work with NovImmune  on the development and potential commercialization of this anti-IL-17 antibody. We are hopeful that it has the potential to benefit patients across a range of autoimmune diseases.”

NovImmune SA
NovImmune SA (‘NovImmune’) is a drug discovery and development company with a focus on therapeutic mAbs for inflammatory diseases and immune-related disorders.
NovImmune has generated, to date, seven proprietary mAbs. The pipeline is a balance of preclinical and clinical compounds, with a mix of both clinically validated as well as novel targets. Each of these portfolio products has the potential to become a medicine for multiple medical conditions due to the overlapping mechanism of action under laying these types of diseases.
Three compounds are at this time in clinical development, with the most advanced in Phase II. The company has currently 70 employees based in Plan-les-Ouates/Geneva, Switzerland.
For more information please visit our website: www.novimmune.com.

About Genentech
Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.



For further information please contact:

Luca Bolliger
Director, Business Development and Communication
NovImmune SA
14, ch. des Aulx
1228 Plan-Les-Ouates
Geneva Switzerland

T +41 22 593 51 15
F +41 22 839 71 42

 
Jack Barbut
CEO
NovImmune SA
14, ch. des Aulx
1228 Plan-Les-Ouates
Geneva Switzerland

T +41 22 839 71 41
F +41 22 839 71 42

Find an actor

Life Science to Turkey28.03.2017

Switzerland Global Enterprise is organizing a fact finding mission to Turkey for Swiss companies who would like to...

BioAlps Bridging the World : Worldwide Visibility Package 2017

A yearly international programme for our affiliated companies to increase their visibility
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

E-mail address
Powered by /boomerang